Evidence map›Paper›PMID 26261778›Full record

ArticleWorld journal of critical care medicine2015

Outcomes of critically ill cancer patients with Acinetobacter baumannii infection.

Silvio A Ñamendys-Silva, Paulina Correa-García, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Patricia Cornejo-Juárez, Abelardo Meneses-García

Open access · hybridAbstract read
In one paragraph

Article in World journal of critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Risk factors for acquiringAccess microbiology · 2023
    Article
  3. Frontiers in microbiology · 2023
    Review
  4. Article
  5. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
  6. Risk Factors, Clinical Presentation, and Outcome ofFrontiers in cellular and infection microbiology · 2017
    Article
  7. Article
  8. Frontiers in cellular and infection microbiology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Silvio A Ñamendys-SilvaSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Paulina Correa-GarcíaSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Francisco J García-GuillénSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
María O González-HerreraSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Américo Pérez-AlonsoSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Julia Texcocano-BecerraSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Angel Herrera-GómezSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Patricia Cornejo-JuárezSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Abelardo Meneses-GarcíaSilvio A Ñamendys-Silva, Francisco J García-Guillén, María O González-Herrera, Américo Pérez-Alonso, Julia Texcocano-Becerra, Angel Herrera-Gómez, Abelardo Meneses-García, Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Instituto Nacional de Cancerología · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Nacional de las Mujeres · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo describe the intensive care unit (ICU) outcomes of critically ill cancer patients with Acinetobacter baumannii (AB) infection.

methodsThis was an observational study that included 23 consecutive cancer patients who acquired AB infections during their stay at ICU of the National Cancer Institute of Mexico (INCan), located in Mexico City. Data collection took place between January 2011, and December 2012. Patients who had AB infections before ICU admission, and infections that occurred during the first 2 d of ICU stay were excluded. Data were obtained by reviewing the electronic health record of each patient. This investigation was approved by the Scientific and Ethics Committees at INCan. Because of its observational nature, informed consent of the patients was not required.

resultsThroughout the study period, a total of 494 critically ill patients with cancer were admitted to the ICU of the INCan, 23 (4.6%) of whom developed AB infections. Sixteen (60.9%) of these patients had hematologic malignancies. Most frequent reasons for ICU admission were severe sepsis or septic shock (56.2%) and postoperative care (21.7%). The respiratory tract was the most frequent site of AB infection (91.3%). The most common organ dysfunction observed in our group of patients were the respiratory (100%), cardiovascular (100%), hepatic (73.9%) and renal dysfunction (65.2%). The ICU mortality of patients with 3 or less organ system dysfunctions was 11.7% (2/17) compared with 66.6% (4/6) for the group of patients with 4 or more organ system dysfunctions (P = 0.021). Multivariate analysis identified blood lactate levels (BLL) as the only variable independently associated with in-ICU death (OR = 2.59, 95%CI: 1.04-6.43, P = 0.040). ICU and hospital mortality rates were 26.1% and 43.5%, respectively.

conclusionThe mortality rate in critically ill patients with both HM, and AB infections who are admitted to the ICU is high. The variable most associated with increased mortality was a BLL ≥ 2.6 mmol/L in the first day of stay in the ICU.

Indexed as

Acinetobacter baumanniiCancer patientsCritical careIntensive careOutcomes

Identifiers

PMID26261778
PMCPMC4524823
OpenAlexW2406239962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.